Germline mutations in BRAF cause cardio-facio-cutaneous syndrome (CFCS), whereby 40% of patients develop hypertrophic cardiomyopathy (HCM). As the role of the RAS/MAPK pathway in HCM pathogenesis is unclear, we generated a human induced pluripotent stem cell (hiPSC) model for CFCS from three patients with activating BRAF mutations. By cell sorting for SIRPa and CD90, we generated a method to examine hiPSC-derived cell type-specific phenotypes and cellular interactions underpinning HCM. BRAFmutant SIRPa + /CD90 À cardiomyocytes displayed cellular hypertrophy, pro-hypertrophic gene expression, and intrinsic calciumhandling defects. BRAF-mutant SIRPa À /CD90 + cells, which were fibroblast-like, exhibited a pro-fibrotic phenotype and partially modulated cardiomyocyte hypertrophy through transforming growth factor b (TGFb) paracrine signaling. Inhibition of TGFb or RAS/MAPK signaling rescued the hypertrophic phenotype. Thus, cell autonomous and non-autonomous defects underlie HCM due to BRAF mutations. TGFb inhibition may be a useful therapeutic option for patients with HCM due to RASopathies or other etiologies.
INTRODUCTION
The RASopathies are developmental disorders caused by mutations in the RAS/MAPK pathway, characterized by pleomorphic developmental defects including facial dysmorphism, short stature, neurocognitive delay, and cardiac defects. One of the commonest cardiac manifestations is hypertrophic cardiomyopathy (HCM) (Tartaglia and Gelb, 2010) .
HCM is defined as thickening of the myocardium that occurs in the absence of an underlying insult, usually resulting from mutations in various genes encoding sarcomeric components. Histologically, there is cardiomyocyte (CM) enlargement and increased fibrosis. HCM is molecularly characterized by upregulation of a fetal gene program including increased expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), often with dysregulated calcium handling . About 70% of patients with HCM develop obstruction, while other complications include arrhythmias, heart failure, and sudden cardiac death (Harris et al., 2006) .
The role of RAS/MAPK signaling in cardiac hypertrophy remains unclear. Cardiac-restricted overexpression of Mek1 caused compensated hypertrophy with increased cardiac function (Bueno et al., 2000) . In addition,
Erk1
À/À Erk2 +/À mice were not protected from pressure overload or agonist stimulation (Purcell et al., 2007) . However, oncogenic Hras over-expression led to pathological hypertrophy with fibrosis and calcium-handling defects (Hunter et al., 1995; Zheng et al., 2004) , and dominant-negative Raf1 overexpression prevented pressure overload-induced cardiac hypertrophy (Harris et al., 2004) . Some suggest that the pathological effects of RAS and RAF signaling may not be exclusively mediated by downstream MAPK signaling but rather by cross-activation of other pathways (Heineke and Molkentin, 2006) . Mice expressing the RASopathy Raf1 L613V allele developed HCM, rescued by MEK inhibition . However, mice with activating BRAF mutations did not exhibit pathological cardiac remodeling (Andreadi et al., 2012; Urosevic et al., 2011) . Thus, the pathogenesis of HCM in cardiofacio-cutaneous syndrome (CFCS), whereby 75% of cases have germline BRAF mutations (Rodriguez-Viciana et al., 2006) and 40% develop HCM (Armour and Allanson, 2008) , is unclear. To study this, we generated an hiPSC model of CFCS and developed a method to examine hiPSC-derived cell type-specific phenotypes and cellular interactions underpinning HCM by cell sorting based on SIRPa and CD90 expression. We show that purified CMs derived from hiPSCs harboring the CFC-causing T599R or Q257R BRAF mutations display cellular hypertrophy and intrinsic calcium-handling defects. In addition, fibroblastlike cells (FLCs) derived from BRAF-mutant hiPSCs exhibit pro-fibrotic behavior and modulate the hypertrophic phenotype through paracrine transforming growth factor b (TGFb) signaling. Both TGFb and RAS/MAPK inhibition rescue the hypertrophic phenotype.
RESULTS
Generation and Purification of Wild-Type and BRAF-Mutant iPSC-Derived CMs hiPSCs were generated from dermal fibroblasts from three unrelated patients with CFCS. Patient 1 (BRAF1) harbored the known BRAF T599R mutation (Yoon et al., 2007) , which alters the activation segment of the kinase domain and is kinase activating (Wan et al., 2004) . Patients 2 and 3 (BRAF2, BRAF3) harbored BRAF Q257R mutations, the commonest CFCS mutation, which alters the cysteine-rich domain of the conserved region 1 (CR1) and is also kinase activating (Rodriguez-Viciana et al., 2006) . Patients 1 and 2 displayed HCM while patient 3 did not. Wild-type (WT) hiPSC lines generated from three unrelated healthy individuals served as controls. DNA sequencing confirmed the heterozygous BRAF mutations in mutant hiPSC lines ( Figure 1A ). Mutant lines had normal karyotypes, and pluripotency was confirmed with immunofluorescence, gene expression, and tri-lineage differentiation assays ( Figure S1 ). hiPSCs were differentiated along a cardiogenic lineage as 3D embryoid bodies (EBs) using a modification of an established protocol (Yang et al., 2008) (Figure 1B ). In addition to three WT hiPSC lines, two clones from each mutant hiPSC line were used in subsequent experiments (Table  S1 ). Spontaneous beating was observed between days 10 and 12 of differentiation. To detect potential molecular defects intrinsic to CMs and non-CMs, we purified these populations separately using flow cytometry based on their expression of SIRPa, a CM marker (Dubois et al., 2011) , and CD90, a marker that labels the majority of non-CMs derived from PSCs (Dubois et al., 2011; Kisselbach et al., 2009 Figure S2 ). (Figure 2A ). Using flow cytometry to analyze forward scatter (FSC) as a surrogate of 3D cellular size, BRAF-mutant CMs were also larger than WT CMs ( Figure S3 ). Increased sarcomeric organization, a hallmark of cardiac hypertrophy (Aoki et al., 2000) demonstrated by a striated cTNT staining pattern, was apparent in BRAF-mutant CMs (58%) compared with WT (16%; p < 0.0001). The most pronounced sarcomere organization was observed in severely hypertrophied BRAF-mutant CMs ( Figure 2B ). Upregulation of a fetal gene program, classically observed in HCM (Kuwahara et al., 2003) , was also noted in purified BRAF-mutant CMs, which displayed >5-fold and >6-fold increased expression of ANP and BNP, respectively, compared with WT (p < 0.0001), as well as a >8-fold increased b-myosin heavy chain (MYH7) to a-myosin heavy chain (MYH6) ratio (p = 0.078) ( Figure 2C ).
Purified BRAF-Mutant CMs Display Altered Calcium Handling Dysregulation of calcium (Ca 2+ ) handling has been observed in many HCM models (Molkentin, 2004) , including an hiPSC model of familial HCM (Lan et al., 2013) . In purified BRAF-mutant CMs, phospholamban (PLN) expression was significantly decreased (p = 0.016) ( Figure 2C ) with a trend toward increased SERCA2a expression (data not shown). Figure 3A ). Consistent with increased Ca 2+ release observed in mouse hearts overexpressing SERCA2a (Baker et al., 1998) , BRAF-mutant CMs also displayed increased Ca
2+
release from the SR, as reflected by increased transient amplitude compared with WT (3.6 a.u. versus 2.6 a.u., p < 0.0001) ( Figure 3B ). Exposure to the ryanodine receptor activator caffeine revealed that BRAF-mutant CMs contained increased stored Ca 2+ compared with WT (6.2 a.u.
versus 4.5 a.u., p < 0.001) ( Figure 3C ), similar to observations during early cardiac hypertrophy (Delbridge et al., 1997; Sipido et al., 2000 Figure S5A ). In contrast, ERK activation was not increased in BRAF-mutant CMs compared with WT CMs ( Figure 4A ). The contribution of non-CMs as crucial to the hypertrophic response has been increasingly recognized (Fujiu and Nagai, 2014) . To address whether BRAF-mutant non-CMs display activation of the RAS/MAPK pathway, we purified the SIRPa À /CD90 + population ( Figure 1C Figure S4A ). Within cardiac tissue, fibroblasts exclusively express DDR2 (Camelliti et al., 2005) . In addition, hiPSC-derived CD90 + cells displayed a spindleshaped morphology similar to fibroblasts ( Figure S4B ). Thus, we henceforth refer to CD90 + /SIRPa À cells as FLCs.
BRAF-mutant FLCs displayed increased ERK activation compared with WT FLCs, with significantly larger activation in the basal state (1.8 a.u. versus 0.9 a.u., p = 0.0059) ( Figure 4B ). Importantly, activation of AKT was not observed in BRAF-mutant CMs or FLCs (Figures S5B and S5C) , distinct from AKT/mTOR involvement in a related RASopathy syndrome due to PTPN11 mutations (Marin et al., 2011) , but similar to findings in mice with mutations in RAF isoforms .
BRAF-Mutant FLCs Are Pro-fibrotic and Influence the Hypertrophic Phenotype
To investigate whether activated BRAF-mutant FLCs were modulating the CM hypertrophic phenotype, we cocultured purified WT CMs along with purified WT or BRAF-mutant FLC populations ( Figure 5A ). Strikingly, the cellular area of WT CMs doubled when co-cultured with BRAF-mutant FLCs compared with WT FLCs (p < 0.0001) ( Figures 5B and 5C ).
Next, we examined whether BRAF-mutant FLCs displayed behavior similar to activated fibroblasts in the setting of fibrosis. Compared with WT, BRAF-mutant FLCs were hyperproliferative (15% versus 7%, p = 0.03) ( Figure 5D ). BRAF-mutant FLCs also expressed significantly increased levels of fibrosis-associated genes, including TGFb1 (p = 0.002), periostin (POSTN) (p = 0.01), connective tissue growth factor (CTGF) (p = 0.002), and collagen type I (COL1A2) (p = 0.003), and a trend toward increased expression of endothelin-1 (ET-1) (p = 0.07) ( Figure 5E ). Thus, the BRAF-mutant FLCs displayed a pro-fibrotic phenotype with upregulation of several TGFb pathway members, suggesting a role for TGFb signaling in mediating the hypertrophic response.
BRAF-Mutant FLCs Influence CM Hypertrophy through Paracrine TGFb1 Secretion
To determine whether the effect of the BRAF-mutant FLCs on the hypertrophic phenotype was mediated by a paracrine effect, we cultured purified WT and BRAF-mutant CMs with conditioned media from purified WT and BRAF-mutant FLCs ( Figure 6A ). Remarkably, when WT CMs were exposed to BRAF-mutant FLC conditioned media, their cellular area nearly doubled (p < 0.0001) and was similar to that of BRAF-mutant CMs exposed to BRAF-mutant FLC conditioned media. Exposure to BRAFmutant FLC conditioned media also resulted in significantly increased ANP expression in WT CMs (p = 0.03). When BRAF-mutant CMs were cultured with WT FLC conditioned media, their cellular area decreased by 30% (p = 0.008) ( Figures 6B-6D ). Thus, we concluded that BRAF-mutant FLCs were modulating CM hypertrophy through a paracrine mechanism.
TGFb has been implicated in signaling between fibroblasts and CMs, mediating hypertrophic growth (Gray et al., 1998; Koitabashi et al., 2011) . Using an ELISA, we found that the amounts of active and total TGFb protein secreted by BRAF-mutant FLCs were increased compared with those from WT cells. No difference in TGFb1 gene expression or secreted TGFb protein level was observed between BRAF-mutant and WT CMs ( Figures S6A-S6C ). To verify whether the paracrine effect of the BRAFmutant FLCs was mediated by increased TGFb secretion, we pre-incubated conditioned media with a pan-TGFb neutralizing antibody (TGFb-NA). TGFb-NA-treated conditioned media from BRAF-mutant FLCs failed to produce a hypertrophic effect on WT or BRAF-mutant CMs (p = 0.01), and resulted in significantly decreased expression of BNP in BRAF-mutant CMs (p = 0.008) ( Figures 6B, 6C , and 6E). Thus, we concluded that TGFb signaling was necessary for the hypertrophy observed in the BRAFmutant CMs.
To determine whether TGFb signaling was sufficient for the induction of CM hypertrophy, we incubated CMs with recombinant human TGFb (rhTGFb). Upon exposure to rhTGFb, the cellular area of BRAF-mutant and WT CMs significantly increased (p < 0.0001 and p = 0.03, respectively) ( Figure S6D ). Exposure of purified CMs to TGFb-NA demonstrated no significant change in their cellular area, further implicating the source of increased TGFb as derived from BRAF-mutant FLCs rather than BRAF-mutant CMs.
Together, our results reveal non-CM autonomous defects in BRAF-mutant FLCs, which contribute to the hypertrophic phenotype observed in BRAF-mutant CMs through increased TGFb signaling.
Activation of the RAS/MAPK Pathway Induces the Hypertrophic Phenotype
To test whether MEK inhibition could ameliorate the hypertrophic phenotype in hiPSC-derived CMs, we exposed a mixed population of CMs and non-CMs to the MEK inhibitor U0126. While U0126 treatment had no effect on WT CM cellular area, the cellular area of BRAF-mutant CMs was reduced by 36% (p < 0.0001) to a size not significantly different from WT ( Figure 7A ), likely due to MEK inhibition affecting BRAF-mutant FLCs. In addition, treatment of purified BRAF-mutant CMs in the absence of FLCs with U0126 normalized their intrinsic Ca 2+ -handling defects, including decreasing the percentage of irregular transients and SR Ca 2+ content to levels not significantly different from WT ( Figures 7B and 7C ).
To document further that the CM hypertrophy was due to BRAF gain of function, we exposed purified WT and BRAF-mutant CMs to conditioned media from WT or BRAF-mutant FLCs that had or had not been treated with the BRAF inhibitor GDC-0879 (GDC). Both WT and BRAF-mutant CMs displayed significantly reduced cellular area after exposure to conditioned media taken from BRAF-mutant FLCs treated with GDC (p = 0.01 and p = 0.0006, respectively) ( Figures S7A and S7B) . To demonstrate whether activated BRAF was sufficient to induce CM hypertrophy, we overexpressed BRAF T599R cDNA in WT hiPSCs (WT-T599R). The presence of mutant cDNA was confirmed by Sanger sequencing, and increased expression of BRAF was confirmed by qPCR ( Figure S7C ). Compared with conditioned media from WT FLCs expressing only an empty vector, exposure to conditioned media from WT-T599R FLCs induced significantly increased cellular area (p = 0.02) and expression of ANP and BNP in WT CMs. Expression of those genes reached levels similar to those observed with BRAF-mutant CMs exposed to BRAF-mutant FLC conditioned media (Figures S7D-S7F ). The largest enlargement in cellular area was observed in WT-T599R CMs exposed to WT-T599R FLC conditioned media (p < 0.0001). These data suggest that overactivation of BRAF and the RAS/MAPK pathway can engender CM hypertrophy. . WT CMs exposed to BRAF-mutant Fib-like conditioned media (n = 97) became significantly enlarged compared with exposure to WT Fib-like conditioned media (n = 91) (****p < 0.0001). This effect was prevented by pre-incubation with TGFb-NA (n = 92). Cellular hypertrophy in BRAF-mutant CMs (n = 86) was significantly reduced upon incubation with WT Fib-like conditioned media (n = 88) (**p = 0.008), or pre-incubation of BRAF-mutant Fib-like conditioned media with TGFb-NA (n = 134) (*p = 0.01). Box-and-whisker plots show the median to the first and third quartiles and the minimum and maximum values. ns, not significant. (D) WT CMs exposed to BRAF-mutant Fib-like conditioned media upregulated ANP (n = 3) compared with WT Fib-like conditioned media (n = 3) (*p = 0.03). Data are presented as means ± SEM.
DISCUSSION
(legend continued on next page) in patients 1 and 2, both diagnosed with HCM. Similar subclinical pathology has been demonstrated in other hiPSC models of HCM (Lan et al., 2013) . However, it is also possible that more complex factors active in 3D multi-organ systems such as hemodynamic load, which are inadequately modeled using the 2D hiPSC system, may play a role in disease progression. We recently generated a 3D human engineered cardiac tissue (hECT) model, in which BRAF-mutant hECTs displayed increased twitch force and contraction and relaxation rates, and a lower excitation threshold compared with WT (Cashman et al., 2016) . In the future, these hECT models may be helpful for investigating more complex factors such as tissue perfusion, flow dynamics, and mechanical stress, to (E) BRAF-mutant CMs exposed to BRAF-mutant Fib-like conditioned media (n = 3) upregulated BNP expression (**p = 0.001), which was rescued upon exposure to conditioned media with TGFb-NA (n = 3) (**p = 0.008), to levels similar to those in WT CMs exposed to WT Fiblike conditioned media (n = 3). Data represent three biological replicates (WT1, 2, 3; BRAF1, 2, 3) for conditioned media experiments, and two biological replicates (WT2, 3; BRAF1, 2) for TGFb-NA experiments. Three technical replicates were performed for all conditions. See also Figure S6 . Exposure to U0126 (n = 130) significantly decreased the cellular area of BRAF-mutant CMs (n = 142) by 36% (****p < 0.0001), but had no significant effect (ns) on the cellular area of WT CMs (n = 57). Box-and-whisker plots show the median to the first and third quartiles and the minimum and maximum values. Scale bars, 200 mm. (B and C) Purified BRAF-mutant CMs exposed to U0126 displayed (B) decreased prevalence of irregular transients (n = 34) (****p < 0.0001) and (C) decreased SR Ca 2+ content (n = 12) (***p < 0.001). Data are presented as means ± SEM. n.s., not significant. Data represent two (WT2, 3) and three (BRAF1, 2, 3) biological and four technical replicates. See also Figure S7 . enable higher-fidelity physiologic measurements of muscle function.
Some aspects of the intrinsic CM phenotype we document have been associated with enhanced cellular maturation in culture, including organized sarcomeres and increased cellular area (Yang et al., 2014) . However, matured stem cell-derived CMs develop into elongated rods with myofibrils arranged parallel to the long axis of the cell, and do not display the irregular, generalized increase in cellular area that we observed. In addition, immature derived CMs possess sophisticated excitationcontraction coupling and do not display increased Ca 2+ transient amplitude, irregularity, or increased SR Ca 2+ stores upon maturation (Lundy et al., 2013) . Although genotype-specific influences on CM maturation may contribute to the CM phenotype, the HCM phenotype we observe in its totality cannot be attributed to them. In addition, the variations in cardiac differentiation efficiencies we document do not segregate WT and mutant populations and are unrelated to CM maturation, as SIRPa expression is detected in stem cell-derived CMs between days 7 and 8 of differentiation (Dubois et al., 2011) .
Our data also reveal variability in behavior among hiPSC lines (Figures 2, 3 , and 4), often attributed to variations that occur during re-programming (Toivonen et al., 2013) and to distinct genetic backgrounds. This variability cannot be attributed to a single cell line and is not replicated across distinct experiments. To strengthen our conclusions, we have utilized six independent patient samples and provided inhibitory and overexpression studies, which support our claims.
To date, hiPSC models for cardiac disease have utilized mixed cell populations (Lan et al., 2013; Zanella et al., 2014) , obscuring possible contributions of neighboring cells to the disease phenotype. Here, we developed an effective dual-purification method to study cell interactions underpinning human HCM. By combining CM and non-CM markers, we increased hiPSC-derived CM purity from <70% (Dubois et al., 2011) to >95% while simultaneously purifying the non-CM fraction. While CD90 is a well-described marker for human fibroblasts (Kisselbach et al., 2009 ), it has also been shown to label stem cells, lymphocytes, neurons, and activated endothelial cells (Herrera-Molina et al., 2013) . As CM differentiation protocols direct mesodermal lineage formation (Mummery et al., 2012) , robust stem cell differentiation into many of these cell types is unlikely. The expression of multiple fibroblast-and fibrosis-associated genes in CD90 + cells supports their likely identity as FLCs. The importance of the interaction between fibroblasts and CMs in cardiac hypertrophy has been previously demonstrated. In neonatal rat and mouse CMs, hypertrophy was dependent on exposure to fibroblasts or their conditioned media, and was mediated by fibroblast paracrine TGFb1 release (Fredj et al., 2005; Gray et al., 1998) . AngII induces a pro-fibrotic phenotype in fibroblasts, stimulating proliferation, collagen synthesis, and extracellular matrix proteins (Bouzegrhane and Thibault, 2002) , mediated by upregulation and secretion of various factors including TGFb (Kawano et al., 2000) . In vivo, the hypertrophic response to AngII treatment or pressure overload was dependent on TGFb signaling (Kuwahara et al., 2002; Schultz Jel et al., 2002) . In these models, exogenous stimuli were utilized to induce cardiac hypertrophy, a phenomenon distinct from HCM. Here, we have shown in a human HCM model due to elevated RAS/MAPK signaling that paracrine TGFb signaling from FLCs to CMs directly stimulates the hypertrophic response. Indeed, it has been shown that AngII stimulates TGFb synthesis in cardiac fibroblasts through activation of the MAPK substrate ELK-1 in humans (Kawano et al., 2000) . In a mouse model of familial HCM due to aMHC mutations, cardiac fibrosis was mediated by non-myocyte proliferation and TGFb signaling (Teekakirikul et al., 2010) . In this model, mutant CMs were shown to activate the non-myocyte population, which then contributed to fibrosis. The ability of activated fibroblasts to directly stimulate cardiac hypertrophy, in addition to their well-known role in fibrosis, may be conserved in other etiologies of HCM, although the mechanism of fibroblast activation may be different.
Inhibition of TGFb abolished the ability of BRAF-mutant FLCs to induce CM hypertrophy, suggesting that TGFb inhibition may provide therapeutic benefit to CFCS patients with HCM. Few pre-clinical and clinical studies have demonstrated therapeutic efficacy of TGFb inhibition in HCM. In mice with sarcomeric mutations, TGFb pathway inhibition prior to or after the onset of HCM normalized several pathological features, such as non-myocyte proliferation, pro-fibrotic gene expression (Teekakirikul et al., 2010) , and interstitial fibrosis (Lim et al., 2001) . In small clinical studies, patients with existing HCM treated with losartan exhibited improved diastolic function (Araujo et al., 2005) , decreased ventricular mass, and reduced fibrosis (Shimada et al., 2013) . These studies suggest a potential therapeutic role for TGFb inhibition in HCM due to various etiologies. Our work also directly implicates activation of the RAS/MAPK pathway in HCM, as inhibition of MEK or BRAF rescued the hypertrophic phenotype while overexpression of activated BRAF induced CM hypertrophy. While there has been no clinical trial conducted to assess the effect of MEK inhibition on hypertrophy in RASopathy patients, MEK inhibition has been associated with an extensive side-effect profile in humans (Akinleye et al., 2013) . More work is necessary to determine whether TGFb inhibition would be preferable to MEK inhibition in the treatment of RASopathy-associated HCM, particularly in patients with well-established disease with significant fibrosis.
In summary, we have shown that activation of the RAS/ MAPK pathway leads to CM hypertrophy driven by CM autonomous and non-autonomous defects. We describe a potential therapeutic benefit of TGFb inhibition or RAS/ MAPK inhibition for HCM in CFCS patients, for which no curative option exists. TGFb inhibition may find therapeutic efficacy in patients with HCM of various etiologies.
EXPERIMENTAL PROCEDURES hiPSC Generation and Maintenance
BRAF1 dermal fibroblasts were obtained from an 18-year-old female with HCM. BRAF1 hiPSCs were generated using retroviral pMXbased vectors encoding human OCT3/4, SOX2, KLF4, and c-MYC as previously published (Carvajal-Vergara et al., 2010) with modifications. Retrovirus was added to fibroblasts 24 and 48 hr after plating. After day 4 the medium was changed every 2 days, and hESC-like colonies were isolated after 30 days. BRAF2 and BRAF3 dermal fibroblasts were obtained from a 13-year-old female with HCM and a 2-year-old male without evidence of HCM, respectively. BRAF2 and BRAF3 hiPSC lines were generated using episomal-based vectors as previously described (Okita et al., 2011) , with modifications. One microgram of each plasmid pCXLE-hOCT3/4-shp53-F, pCXLE-hSK, pCXLE-hUL, and pCXLE-EGFP (Addgene) was mixed with Resuspension Buffer R (Life Technologies) and added to fibroblasts. Cells were electroporated using the Neon Transfection System (Life Technologies), re-plated, and placed at 37 C. After 5 days, fibroblasts were plated on MEFs and maintained in hiPSC medium. Clones were chosen based on morphology and growth. Pluripotency was verified by immunofluorescence, gene expression, southern blot, and teratoma formation or in vitro tri-lineage differentiation assays. Fully characterized retrovirally generated WT hiPSC lines were separately provided.
Human Fetal Heart and Immortalized Dermal Skin Fibroblast Samples
All samples were obtained according to the ethical guidelines provided by the institutional review board. Human fetal heart was dissociated in 1 mg/mL collagenase B (Roche) for 3 hr at 37 C and the centrifuged pellet resuspended in PBS + 0.1% BSA. Human dermal fibroblasts were immortalized using hTERT lentivirus with 6 mg/mL polybrene. After 2 days, cells were selected with 10 mg/mL blasticidin. Drug-resistant colonies were maintained in 10 mg/mL blasticidin and expanded for further use.
Southern Blot and Karyotyping
Two micrograms of gDNA from retrovirally generated hiPSCs was digested with BglII, separated on a 0.8% agarose gel, transferred to a positively charged nylon membrane, and hybridized with DIG-labeled human OCT4, SOX2, KLF4, and MYC cDNA probes. Membranes were washed, blocked, and incubated with anti-DIG-AP Fab fragments (Roche). Probe-target hybrids were incubated with chemiluminescent CDP-Star substrates (Roche) and detected by exposure to X-ray film. For karyotyping, hiPSCs were plated on Matrigel-coated glass coverslip dishes (MatTek), and karyotyping was performed as previously described (Carvajal-Vergara et al., 2010) .
In Vitro Three-Germ-Layer Differentiation hiPSCs generated with episomal vectors were differentiated into three germ layers in vitro using the d-Stem Tri-lineage Differentiation Kit (MicroStem) according to the manufacturer's instructions. hiPSCs were plated on matrix-coated 96-well plates, and day-1 medium was added after 24 hr. Cells were maintained for 3 days (mesoderm) or 6 days (endoderm, ectoderm) at 37 C before fixation. hiPSCs were stained with provided primary antibodies Brachyury (mesoderm), Sox17 (endoderm), or Sox1 (ectoderm) and corresponding Alexa Fluor secondary antibody.
Teratomas
Animal procedures were performed in accordance with the Icahn School of Medicine at Mount Sinai's Institutional Animal Care and Use Committee. Cells (1-2 3 10 6 ) were injected subcutaneously into the right hind leg of immunocompromised NOD-SCID mice (The Jackson Laboratory). Six to ten weeks after injection teratomas were excised, fixed in formalin, embedded in paraffin, sectioned, and stained with H&E by the Histology Service Core Facility at the Icahn School of Medicine at Mount Sinai. Histological evaluation was performed using a Nikon TE2000-U microscope and ACT-1 software.
Mutation Analysis and Sequencing
hiPSC gDNA was purified using the DNeasy Blood & Tissue Kit (Qiagen). PCR amplification of exons 6 and 15 was performed using primers listed in Table S2 . Bioedit Sequence Alignment Editor version 7.0.5.3 was used for sequencing analysis.
hiPSC Differentiation hiPSCs were differentiated as previously described (Carvajal-Vergara et al., 2010) with the following modifications. hiPSCs were cultured on Matrigel-coated plates for 2 days for feeder depletion. For generation of EBs, hiPSCs were dissociated with 1 mg/mL collagenase B (Roche) for 15 min. Cell clumps were centrifuged at 200 3 g for 2 min, and resuspended to clusters of 50-100 cells in differentiation medium containing StemPro 34 (Life Technologies), 2 mM L-glutamine (Life Technologies), 4 3 10 À4 M monothioglycerol (Sigma), 50 mg/mL ascorbic acid (Sigma), and 150 mg/mL transferrin (Roche). EBs were maintained in 6-well ultra-low attachment plates (Corning) at 37 C in 5% CO 2 , 5% O 2 , and 90% N 2 . Differentiation medium was supplemented with 10 ng/mL BMP4 (R&D Systems) (day 0), 10 ng/mL BMP4 (R&D Systems) and 15 ng/mL Activin A (Peprotech) (day 1), and 1.5 mM IWR-1 (Sigma) (day 4). After day 8, the medium was changed every 5 days to medium without supplements. EBs were prepared for cell sorting on day 25 of differentiation.
Flow Cytometry
EBs were dissociated in 1 mg/mL collagenase B (Roche) overnight at 37 C. CMs were stained with 1:500 anti-human SIRPa-PE/Cy7
(BioLegend #323807) and 1:250 anti-human CD90-FITC (BD Pharmingen #555595) for 1 hr at 4 C in PBS + 10% FBS staining buffer.
Gates were set using appropriate isotype control antibodies (Biolegend #400125, BD Pharmingen #MOPC-31C 
Cellular Size and Sarcomeric Organization
Single cells were analyzed 4 days after sorting. The 2D cellular area of CMs was determined using ImageJ software by manual outlining of single cTNT + cells. The 3D cellular area was quantified using the mean fluorescence intensity of the FSC channel in SIRPa + /CD90 À cells using FlowJo software, version 9.3.2. Sarcomeric organization was defined as the presence of a striated pattern of cTNT immunofluorescence in >50% of the cellular area, indicating the development of organized contractile filaments. Measurements were blinded and replicated by several independent observers.
Gene Expression
Total RNA was extracted using TRIzol (Life Technologies) and RNeasy Plus mini kit (Qiagen). Total RNA was reverse transcribed using oligo(dT) primers with the Superscript II Synthesis Kit (Life Technologies). qPCR was performed using Fast SYBR Green Master Mix (Applied Biosystems) according to the manufacturer's instructions. Expression levels were calculated using the DDCt method and normalized to GAPDH. Real-time qPCR was performed on a StepOne Plus Real-Time PCR System (Applied Biosystems) and analyzed with the StepOne Software v2.2.2. Primers used in qPCR assays are listed in Table S2 . 
Calcium Transient Analysis

TGFb ELISA
Secretion of total and active TGFb into conditioned medium was quantified using ELISA assays according to the manufacturer's instructions (BosterBio). rhTGFb (R&D systems #240-B-002) was used for the standards. For active TGFb levels, conditioned medium was incubated with 1 N HCl and 1.2 N NaOH/0.5 M HEPES. Samples and standards were added to TGFb monoclonal antibody pre-coated 96-well plates and incubated for 90 min at 37 C. Biotinylated antibodies were added and incubated at 37 C for 1 hr.
After washing with 0.01 M PBS, ABC working solution was added and incubated at 37 C for 30 min. After washing, TMB color developing agent was added and the plate incubated at 37 C in the dark for 30 min. TMB stop solution was added and the OD absorbance at 450 nm was recorded in a microplate reader (Promega).
Co-culture and Conditioned Media Studies
For co-culture studies, cells were mixed and re-plated on Matrigelcoated tissue-culture plates at a ratio of 60% FLCs/40% CMs in basic differentiation medium and fixed after 4 days. For conditioned media studies, 2.5 3 10 4 purified CMs and 10 5 purified
FLCs were re-plated separately on Matrigel-coated 24-well tissueculture dishes in basic differentiation medium. GDC-0897 (SelleckChem) or DMSO at 10 mM was added to FLCs for 4 days. Conditioned medium was then collected from FLCs and added to CMs. Ten micrograms of TGFb-NA (R&D Systems #MAB1835) was incubated with FLC conditioned medium for 90 min prior to CM exposure. U0126 (Promega) or DMSO at 5 mM was added directly to co-cultured cells. After an additional 4 days, CMs were fixed to analyze cell area and gene expression. Ca 2+ transients were analyzed 5 days after U0126 treatment. For analysis of the direct effect of TGFb on cell size, purified CMs were plated at 2.5 3 10 4 cells per well and treated with either 1 ng/mL rhTGFb or 10 ng/mL TGFb-NA, and cell size was analyzed after 4 days.
Proliferation Analysis
Cells were resuspended in PBS at 10 6 cells/mL. One microliter of reconstituted LIVE/DEAD Fixable Blue stain (Life Technologies) was added to the cells at 25 C for 30 min in the dark. Cells were fixed and stained with 5 mL of Alexa Fluor 647 mouse anti-human Ki-67 (BD Pharmingen #561126) for 30 min at 25 C in the dark and analyzed on an LSR-II flow cytometer (BD Biosciences).
Lentiviral Overexpression
The pSIN-EF2-LIN28-PURO transfer plasmid (Addgene #16580) was used for lentiviral production. LIN28 coding region was removed by restriction enzyme digestion and replaced with BRAF T599R cDNA or nothing (empty vector). Packaging plasmid pCMV-dR8.2-dvpr (Addgene #8455) and envelope plasmid pCMV-VSV-G (Addgene #8454) were used for subsequent viral production. HEK293T cells were transfected with transfer, packaging, and envelope plasmids using the Superfect Transfection Reagent (Qiagen), and maintained at 37 C. At 48 and 72 hr post transfection, medium containing viral particles was collected and used for two rounds of infection of WT1 and WT2 iPSC lines. Clones were selected by puromycin resistance and verified for viral integration via PCR, Sanger sequencing, and qPCR for overexpression of BRAF.
Statistics
The t test was used for single comparisons. One-way ANOVA was used for multiple comparisons, with individual differences analyzed by Tukey's or Dunnett's post test. p Values <0.05 were considered statistically significant. The number of asterisks indicates the significance level: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Data are presented as means ± SEM. Box-andwhisker plots show the median to the first and third quartiles and the minimum and maximum values. 
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